Related references
Note: Only part of the references are listed.Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results
Stefan Zeuzem et al.
ANTIVIRAL THERAPY (2013)
INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS
G. T. Everson et al.
JOURNAL OF HEPATOLOGY (2013)
ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY
E. J. Gane et al.
JOURNAL OF HEPATOLOGY (2013)
SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333+/- RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY
K. V. Kowdley et al.
JOURNAL OF HEPATOLOGY (2013)
SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)
M. S. Sulkowski et al.
JOURNAL OF HEPATOLOGY (2013)
SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL
M. Manns et al.
JOURNAL OF HEPATOLOGY (2013)
SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL
I. Jacobson et al.
JOURNAL OF HEPATOLOGY (2013)
FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAIVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL
P. Ferenci et al.
JOURNAL OF HEPATOLOGY (2013)
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
Christian M. Lange et al.
JOURNAL OF HEPATOLOGY (2013)
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Kris V. Kowdley et al.
LANCET (2013)
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Eric Lawitz et al.
LANCET INFECTIOUS DISEASES (2013)
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus
Ludmila Prokunina-Olsson et al.
NATURE GENETICS (2013)
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Ralf Bartenschlager et al.
NATURE REVIEWS MICROBIOLOGY (2013)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Edward J. Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment of HCV Infection by Targeting MicroRNA
Harry L. A. Janssen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in US Primary Care Settings
David B. Rein et al.
ANNALS OF INTERNAL MEDICINE (2012)
Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C
Tom W. Chu et al.
GASTROENTEROLOGY (2012)
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
Stefan Zeuzem et al.
HEPATOLOGY (2012)
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy
Christian M. Lange et al.
HEPATOLOGY (2012)
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
Adriaan J. van der Meer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2012)
INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS
E. J. Gane et al.
JOURNAL OF HEPATOLOGY (2012)
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
Stanislas Pol et al.
LANCET INFECTIOUS DISEASES (2012)
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients
Johannes Vermehren et al.
PLOS ONE (2012)
Three-Dimensional Architecture and Biogenesis of Membrane Structures Associated with Hepatitis C Virus Replication
Ines Romero-Brey et al.
PLOS PATHOGENS (2012)
Failure of innate and adaptive immune responses in controlling hepatitis C virus infection
Robert Thimme et al.
FEMS MICROBIOLOGY REVIEWS (2012)
Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
Stefan Zeuzem et al.
GASTROENTEROLOGY (2011)
Ribavirin Potentiates Interferon Action by Augmenting Interferon-Stimulated Gene Induction in Hepatitis C Virus Cell Culture Models
Emmanuel Thomas et al.
HEPATOLOGY (2011)
Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care
Hamish A. Innes et al.
HEPATOLOGY (2011)
Genotypic and Phenotypic Analysis of Variants Resistant to Hepatitis C Virus Nonstructural Protein 5A Replication Complex Inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
Robert A. Fridell et al.
HEPATOLOGY (2011)
IL28B single nucleotide polymorphisms in the treatment of hepatitis C
Christian M. Lange et al.
JOURNAL OF HEPATOLOGY (2011)
Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus
K. Morikawa et al.
JOURNAL OF VIRAL HEPATITIS (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
Gary L. Davis et al.
GASTROENTEROLOGY (2010)
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
Edward J. Gane et al.
LANCET (2010)
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao et al.
NATURE (2010)
Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection
Robert E. Lanford et al.
SCIENCE (2010)
GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796
Matthew F. McCown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
The Cyclophilin Inhibitor Debio 025 Combined with PEG IFNα2a Significantly Reduces Viral Load in Treatment-Naive Hepatitis C Patients
Robert Flisiak et al.
HEPATOLOGY (2009)
A Step Forward in Therapy for Hepatitis C
Jay H. Hoofnagle
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Replication of hepatitis C virus
Darius Moradpour et al.
NATURE REVIEWS MICROBIOLOGY (2007)
Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to pegIFN/RBV: One-year results
N. Afdhal et al.
JOURNAL OF HEPATOLOGY (2007)
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease
Ivo C. Lorenz et al.
NATURE (2006)
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
JJ Feld et al.
NATURE (2005)
Complete replication of hepatitis C virus in cell culture
BD Lindenbach et al.
SCIENCE (2005)
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
T Wakita et al.
NATURE MEDICINE (2005)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
D Lamarre et al.
NATURE (2003)
Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy
T Berg et al.
HEPATOLOGY (2003)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Peginterferon alfa-2a in patients with chronic hepatitis C
S Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
